TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18604045

Group type: EXPERIMENTAL
Intervention: Study group (ventilated with tidal volume of 10 ml/kg and respiratory rate of 15/minute)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (ventilated with tidal volume of 10 ml/kg and respiratory rate of 12/minute)
Number of subjects: 60
Study: 14999362

Group type: EXPERIMENTAL
Intervention: Ultrahaler (3 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Nebulizer (3 mg)
Number of subjects: 12
Study: 11682390

Group type: EXPERIMENTAL
Intervention: Midazolam and ketamine (Group A: 16.67 microg x kg(‐1) x min(‐1) for 30 min, 13.3 microg x kg(‐1) x min(‐1) for 90 min, then 10 microg x kg(‐1) x min(‐1); Group B: 8.33 microg x kg(‐1) x min(‐1) for 30 min, 6.67 microg x kg(‐1) x min(‐1) for 90 min, then 5 microg x kg(‐1) x min(‐1))
Number of subjects: 60

Group type: COMPARATOR
Intervention: Midazolam and ketamine (Group A)
Number of subjects: 60
Study: 10611198

Group type: EXPERIMENTAL
Intervention: Continuous autotransfusion system of ascites (CATSA) performed for 5 hours at a rate of 100-200 ml/h once a day
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Continuous autotransfusion system of ascites (CATSA)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Intravenous albumin supplement (37.5 g/day)
Number of subjects: 54
Study: 9189783

Group type: EXPERIMENTAL
Intervention: Preexercise carbohydrate (CHO) feedings (22.5, 45, or 75 g maltodextrin and dextrose in 473 ml of water)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Preexercise carbohydrate (CHO) feedings
Number of subjects: 8
Study: 1555806

Group type: EXPERIMENTAL
Intervention: Indomethacin gel preparation 1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Indomethacin gel preparation 2
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (placebo or alternative treatment not specified)
Number of subjects: 0
Study: 2581308

Group type: EXPERIMENTAL
Intervention: iohexol
Number of subjects: 54

Group type: COMPARATOR
Intervention: amidotrizoate
Number of subjects: 54
Study: 30064731

Group type: EXPERIMENTAL
Intervention: Proactive psychiatric consultation
Number of subjects: 2177

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 2177
Study: 26780289

Group type: EXPERIMENTAL
Intervention: Relapse to injecting drug use (IDU) after treatment
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: History of IDU prior to treatment
Number of subjects: 161
Study: 24275909

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT), 20 sessions over 5 months
Number of subjects: 70

Group type: COMPARATOR
Intervention: Psychoanalytic psychotherapy, 2 years of weekly sessions
Number of subjects: 70
Study: 22697453

Group type: EXPERIMENTAL
Intervention: Unified Protocol for Transdiagnostic Treatment of Emotional Disorders (UP), n=26
Number of subjects: 37

Group type: COMPARATOR
Intervention: Wait-list control (WLC), n=11
Number of subjects: 37
Study: 20693439

Group type: EXPERIMENTAL
Intervention: Fingertip and palm (N = 41)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Fingertip and forearm (N = 40)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Fingertip
Number of subjects: 84

Group type: COMPARATOR
Intervention: Forearm
Number of subjects: 84

Group type: COMPARATOR
Intervention: Palm
Number of subjects: 84
Study: 18831899

Group type: EXPERIMENTAL
Intervention: High-dose aprotinin
Number of subjects: 28

Group type: COMPARATOR
Intervention: Low-dose aprotinin
Number of subjects: 28
Study: 16134133

Group type: EXPERIMENTAL
Intervention: New drug (low and high dose)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 11821469

Group type: EXPERIMENTAL
Intervention: Preirradiation chemotherapy (2 cycles of ifosfamide, etoposide, methotrexate, cisplatin, and cytarabine), n = 40
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Chemotherapy after irradiation (8 cycles with cisplatin, vincristine, and lomustine), n = 23
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Irradiation (total dose of 35.2 Gy followed by a boost of 20.0 Gy to the primary tumor site), n = 54
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Irradiation (total dose of 54.0 Gy to the tumor region only), n = 7
Number of subjects: 63
Study: 10402369

Group type: EXPERIMENTAL
Intervention: L-arginine treatment
Number of subjects: 34

Group type: COMPARATOR
Intervention: Flare-up GnRHa plus elevated pFSH (Control)
Number of subjects: 34
Study: 7747293

Group type: EXPERIMENTAL
Intervention: 4 ampoules (40 mL) of Brazilian Brothrops polyspecific antivenom
Number of subjects: 340

Group type: COMPARATOR
Intervention: 2 ampoules (20 mL) of Brazilian Brothrops polyspecific antivenom
Number of subjects: 340
Study: 2206784

Group type: EXPERIMENTAL
Intervention: 5 mg verapamil i.v. (8 patients)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 5 mg isosorbide dinitrate sublingually (12 patients)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo infusion (7 patients)
Number of subjects: 20
Study: 30461155

Group type: EXPERIMENTAL
Intervention: Absorbable subcuticular staples
Number of subjects: 206

Group type: COMPARATOR
Intervention: Subcuticular suture
Number of subjects: 206
Study: 28583024

Group type: EXPERIMENTAL
Intervention: Mobile health intervention (Reach Out)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 94
Study: 27422639

Group type: EXPERIMENTAL
Intervention: iHEART intervention (iPhone® equipped with AliveCor® Mobile ECG and Kardia application, plus motivational text messages)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Usual cardiac care
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: iHEART intervention
Number of subjects: 300
Study: 24525963

Group type: EXPERIMENTAL
Intervention: Prophylactic antibiotics (vancomycin/cefepime or piperacillin/tazobactam)
Number of subjects: 38

Group type: COMPARATOR
Intervention: No preventive antibiotics (Control)
Number of subjects: 38
Study: 22561352

Group type: EXPERIMENTAL
Intervention: Structured one‐to‐one behaviour change programme delivered over 14 visits during 12 months by trained advisors
Number of subjects: 381

Group type: COMPARATOR
Intervention: Usual care in general practice
Number of subjects: 381

Group type: EXPERIMENTAL
Intervention: Structured one‐to‐one behaviour change programme
Number of subjects: 381
Study: 19789884

Group type: EXPERIMENTAL
Intervention: iobitridol (350 mgI/ml)
Number of subjects: 307

Group type: COMPARATOR
Intervention: iomeprol (400 mgI/ml)
Number of subjects: 307
Study: 18217911

Group type: COMPARATOR
Intervention: Systemic venous drainage (S-SPK group)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Portal venous drainage (P-SPK group)
Number of subjects: 80
Study: 15880744

Group type: EXPERIMENTAL
Intervention: Fecal occult blood test (FOBT)
Number of subjects: 628

Group type: EXPERIMENTAL
Intervention: Sigmoidoscopy/colonoscopy
Number of subjects: 628

Group type: EXPERIMENTAL
Intervention: Recent FOBT
Number of subjects: 628

Group type: EXPERIMENTAL
Intervention: Recent sigmoidoscopy/colonoscopy
Number of subjects: 628
Study: 12897600

Group type: EXPERIMENTAL
Intervention: Short Form‐36 (SF‐36)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Musculoskeletal Functional Assessment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Disability of the Arm, Shoulder and Hand
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Western Ontario McMaster Osteoarthritis Index (WOMAC)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Simple Shoulder Test
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Roland‐Morris Questionnaire
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oswestry Disability Index
Number of subjects: 0
Study: 10811045

Group type: EXPERIMENTAL
Intervention: Manual Therapy Programme (MTP)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Intensive Training Programme (ITP)
Number of subjects: 180

Group type: COMPARATOR
Intervention: General Practitioner Programme (GPP)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: All treatment programmes
Number of subjects: 180
Study: 8981727

Group type: EXPERIMENTAL
Intervention: Autologous blood transfusion
Number of subjects: 1060

Group type: COMPARATOR
Intervention: Allogeneic blood transfusion
Number of subjects: 1060
Study: 1353192

Group type: EXPERIMENTAL
Intervention: 200,000 IU vitamin A and 40 IU vitamin E every 6 months
Number of subjects: 28753

Group type: COMPARATOR
Intervention: 40 IU vitamin E alone (placebo group)
Number of subjects: 28753
Study: 6091244

Group type: EXPERIMENTAL
Intervention: ACTH 1‐17 (100 micrograms i.v.)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 30698049

Group type: EXPERIMENTAL
Intervention: Preventive swallowing exercise program (3 weekly supervised sessions of 30 min each and home-based exercises 3 times daily)
Number of subjects: 45
Study: 29937396

Group type: EXPERIMENTAL
Intervention: Outcome feedback intervention group
Number of subjects: 2233

Group type: COMPARATOR
Intervention: Treatment-as-usual control group
Number of subjects: 2233
Study: 26667088

Group type: EXPERIMENTAL
Intervention: Aspirin-calcitriol-calcium treatment
Number of subjects: 427

Group type: EXPERIMENTAL
Intervention: Younger subjects (aged 50 years or less)
Number of subjects: 427

Group type: EXPERIMENTAL
Intervention: Older subjects (aged over 70 years)
Number of subjects: 427

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 427

Group type: EXPERIMENTAL
Intervention: Number of adenomas at inclusion
Number of subjects: 427
Study: 24899158

Group type: EXPERIMENTAL
Intervention: High-protein (HP) diet (37.7 en% fat, 25.7 en% protein, 36.6 en% carbohydrates)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Normal-protein (NP) diet (39.4 en% fat, 15.4 en% protein, 45.2 en% carbohydrates)
Number of subjects: 27
Study: 22934397

Group type: EXPERIMENTAL
Intervention: Thermal acupuncture needle muscular stimulation therapy, conducted once a week for 4 weeks.
Number of subjects: 120

Group type: COMPARATOR
Intervention: Celebrex (200 mg, once daily for 4 weeks)
Number of subjects: 120
Study: 20058569

Group type: EXPERIMENTAL
Intervention: 20 ml/kg of Ringer's lactate
Number of subjects: 80

Group type: COMPARATOR
Intervention: 10 ml/kg of Ringer's lactate
Number of subjects: 80
Study: 17415686

Group type: EXPERIMENTAL
Intervention: Carbomer-based artificial tears
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Cellulose-based artificial tears
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Mineral oil-based artificial tears
Number of subjects: 67
Study: 16319703

Group type: EXPERIMENTAL
Intervention: Loose criterion condition (presence/absence judgments)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Strict criterion condition (reading aloud every detected word)
Number of subjects: 160
Study: 12481630

Group type: EXPERIMENTAL
Intervention: Antimicrobial therapy with dexamethasone 0.6 mg/kg/day in 3 divided doses for 4 days
Number of subjects: 68

Group type: COMPARATOR
Intervention: Antimicrobial therapy alone (benzyl penicillin and chloramphenicol for 14 days)
Number of subjects: 68
Study: 9818338

Group type: EXPERIMENTAL
Intervention: Loteprednol etabonate 0.5%
Number of subjects: 227

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 227
Study: 7649710

Group type: EXPERIMENTAL
Intervention: Isokinetic fatigue test to 50% MVC, repeated 3 times
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Recovery immediately following fatigue exercise (Group 1)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Recovery between 3 and 6 minutes (Group 2)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: No recovery during the 8 minute period (Group 3)
Number of subjects: 16
Study: 2565773

Group type: EXPERIMENTAL
Intervention: Training group (n = 21)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Non-training group (n = 10)
Number of subjects: 31
Study: 10941

Group type: EXPERIMENTAL
Intervention: Nitrazepam (10 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Flurazepam hydrochloride (30 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pentobarbitone sodium (200 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30951004

Group type: EXPERIMENTAL
Intervention: Cardiopulmonary resuscitation coach
Number of subjects: 200

Group type: COMPARATOR
Intervention: No cardiopulmonary resuscitation coach
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Roles within teams with a cardiopulmonary resuscitation coach
Number of subjects: 200
Study: 28213957

Group type: EXPERIMENTAL
Intervention: 2 mg kg‐1 b.i.d.
Number of subjects: 64

Group type: COMPARATOR
Intervention: 2 mg kg‐1 t.i.d.
Number of subjects: 64
Study: 26742977

Group type: EXPERIMENTAL
Intervention: Bipolar cautery technique
Number of subjects: 200

Group type: COMPARATOR
Intervention: Ligation technique
Number of subjects: 200
Study: 23242192

Group type: EXPERIMENTAL
Intervention: Home monitoring (HM) of ICD, patients seen once a year unless dysfunction or clinical event occurs.
Number of subjects: 433

Group type: COMPARATOR
Intervention: Ambulatory follow-ups, patients seen every 6 months.
Number of subjects: 433

Group type: EXPERIMENTAL
Intervention: Home monitoring (HM) of ICD.
Number of subjects: 433
Study: 21682833

Group type: EXPERIMENTAL
Intervention: Alogliptin 12.5 mg added to pioglitazone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alogliptin 25 mg added to pioglitazone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo added to pioglitazone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alogliptin (12.5 or 25 mg) during the 40-week extension
Number of subjects: 0
Study: 18272504

Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stents (SES)
Number of subjects: 1012

Group type: COMPARATOR
Intervention: Paclitaxel-eluting stents (PES)
Number of subjects: 1012

Group type: EXPERIMENTAL
Intervention: Diabetic patients
Number of subjects: 1012
Study: 15743867

Group type: EXPERIMENTAL
Intervention: Twin Block (TB) mandibular advancement splint
Number of subjects: 16

Group type: COMPARATOR
Intervention: Herbst mandibular advancement splint (MAS)
Number of subjects: 16
Study: 11836292

Group type: EXPERIMENTAL
Intervention: Recombinant human GH therapy at 27 IU (9 mg)/m(2) x wk
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Recombinant human GH therapy at 18 IU (6 mg)/m(2) x wk
Number of subjects: 58

Group type: COMPARATOR
Intervention: Untreated controls
Number of subjects: 58
Study: 10343539

Group type: EXPERIMENTAL
Intervention: Antiperinuclear factor (APF)
Number of subjects: 279

Group type: EXPERIMENTAL
Intervention: Antikeratin antibodies (AKA)
Number of subjects: 279

Group type: EXPERIMENTAL
Intervention: Antibodies to human epidermis filaggrin (AFA)
Number of subjects: 279

Group type: EXPERIMENTAL
Intervention: Combination of APF and AKA
Number of subjects: 279

Group type: EXPERIMENTAL
Intervention: Combination of AFA and AKA
Number of subjects: 279
Study: 8960842

Group type: EXPERIMENTAL
Intervention: Tight control (systolic < 150/diastolic < 85 mmHg) with beta blocker (atenolol) or ACE inhibitor (captopril)
Number of subjects: 758

Group type: COMPARATOR
Intervention: Less tight control (systolic < 180/diastolic < 105 mmHg)
Number of subjects: 758

Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 758

Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 758

Group type: EXPERIMENTAL
Intervention: Both atenolol and captopril
Number of subjects: 758

Group type: EXPERIMENTAL
Intervention: Tight control (atenolol or captopril)
Number of subjects: 758

Group type: COMPARATOR
Intervention: Less tight control
Number of subjects: 758
Study: 2022136

Group type: EXPERIMENTAL
Intervention: Infant-parent psychotherapy (intervention lasted 1 year, ending when the child was 24 months)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Secure control group (no intervention)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Anxious controls (no intervention)
Number of subjects: 2
Study: 6819904

Group type: EXPERIMENTAL
Intervention: Oral TRH (20 mg twice daily)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Oral metoclopramide (10 mg t.d.s.)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 29855782

Group type: EXPERIMENTAL
Intervention: Closed reduction and percutaneous Kirschner wire fixation (K wire)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Open reduction and internal fixation with mini fragment plates
Number of subjects: 32
Study: 29029687

Group type: EXPERIMENTAL
Intervention: Net‐COPD telemedicine intervention with weekly submission of readings and regular video consultations
Number of subjects: 14
Study: 26026209

Group type: EXPERIMENTAL
Intervention: Dietary fiber (total, soluble and insoluble)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Protein-fiber index (ratio of protein to fiber)
Number of subjects: 40
Study: 25010882

Group type: EXPERIMENTAL
Intervention: fast‐setting addition‐curing silicone (AS)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: fast‐setting polyether (PE)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: fast‐setting PE material
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: fast‐setting AS and PE materials
Number of subjects: 96
Study: 22334770

Group type: EXPERIMENTAL
Intervention: Mometasone furoate/formoterol fumarate (MF/F) 400/10 μg
Number of subjects: 2251

Group type: EXPERIMENTAL
Intervention: Mometasone furoate/formoterol fumarate (MF/F) 400/10 μg, MF 400, F 10
Number of subjects: 2251

Group type: EXPERIMENTAL
Intervention: Mometasone furoate/formoterol fumarate (MF/F) groups
Number of subjects: 2251

Group type: EXPERIMENTAL
Intervention: Mometasone furoate/formoterol fumarate (MF/F) 400/10 μg, MF/F 200/10 μg
Number of subjects: 2251

Group type: EXPERIMENTAL
Intervention: All active treatment groups
Number of subjects: 2251

Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 2251
Study: 19173751

Group type: EXPERIMENTAL
Intervention: Noninvasive ventilation (NIV)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Continuous positive airway pressure (CPAP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: NIV
Number of subjects: 0
Study: 17318620

Group type: EXPERIMENTAL
Intervention: Avaxim 80
Number of subjects: 424

Group type: EXPERIMENTAL
Intervention: Havrix 720
Number of subjects: 424

Group type: EXPERIMENTAL
Intervention: Vaqta 25
Number of subjects: 424

Group type: EXPERIMENTAL
Intervention: Two doses of the same vaccine
Number of subjects: 424

Group type: COMPARATOR
Intervention: Local and systemic adverse events
Number of subjects: 424
Study: 15220672

Group type: EXPERIMENTAL
Intervention: Orally consumed lactobacilli isolated from the vagina
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 11171873

Group type: EXPERIMENTAL
Intervention: At least 2.5 servings/day of vegetables
Number of subjects: 15220

Group type: EXPERIMENTAL
Intervention: Each additional serving/day of vegetables
Number of subjects: 15220

Group type: EXPERIMENTAL
Intervention: At least 2.5 servings/day of vegetables among men with BMI >= 25
Number of subjects: 15220

Group type: EXPERIMENTAL
Intervention: At least 2.5 servings/day of vegetables among current smokers
Number of subjects: 15220
Study: 9787142

Group type: EXPERIMENTAL
Intervention: Intravenous dexamethasone (0.3 mg/kg every 12 hours x 4 doses)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Intravenous dexamethasone
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 7636912

Group type: EXPERIMENTAL
Intervention: High Albumin (supplemental albumin to maintain levels 2.5 to 3.5 g/dL)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Low Albumin (albumin only if levels dropped < 1.5 g/dL)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: High Albumin
Number of subjects: 70

Group type: COMPARATOR
Intervention: Low Albumin
Number of subjects: 70
Study: 2521103

Group type: EXPERIMENTAL
Intervention: Respite or educational services
Number of subjects: 541

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 541
Study: 237493

Group type: EXPERIMENTAL
Intervention: Alclofenac 3 g
Number of subjects: 31

Group type: COMPARATOR
Intervention: Phenylbutazone 300 mg
Number of subjects: 31
Study: 30859363

Group type: EXPERIMENTAL
Intervention: Choline supplementation (30 mg/kg/day)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: DHA supplementation (60 mg/kg/day)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Combined choline and DHA supplementation
Number of subjects: 24

Group type: COMPARATOR
Intervention: Standard nutrition (control)
Number of subjects: 24
Study: 31227681

Group type: EXPERIMENTAL
Intervention: Low-dose wide-detector scan (experimental group)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Low-dose helical scan (low-dose helical group)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Pediatric conventional scan (conventional group)
Number of subjects: 90
Study: 28698884

Group type: EXPERIMENTAL
Intervention: Diabetes
Number of subjects: 1167

Group type: COMPARATOR
Intervention: IFG
Number of subjects: 1167

Group type: COMPARATOR
Intervention: Normoglycaemia
Number of subjects: 1167
Study: 25646186

Group type: EXPERIMENTAL
Intervention: Meaning-centered group psychotherapy (MCGP)
Number of subjects: 253

Group type: COMPARATOR
Intervention: Supportive group psychotherapy (SGP)
Number of subjects: 253
Study: 23570342

Group type: EXPERIMENTAL
Intervention: Diabetic women
Number of subjects: 184

Group type: COMPARATOR
Intervention: Non-diabetic women
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Postmenopausal diabetic females
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Diabetic females
Number of subjects: 184
Study: 21742349

Group type: EXPERIMENTAL
Intervention: Expert-guided tutorial combined with self-directed practice on a procedural trainer
Number of subjects: 39

Group type: COMPARATOR
Intervention: Expert-guided simulator training alone
Number of subjects: 39
Study: 19184087

Group type: EXPERIMENTAL
Intervention: One-running-session trial (T1) - 10 x 1 km interval repeats (90% peak VO2 velocity)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Two-running-session trial (T2) - Continuous 10-km run (70% peak VO2 velocity) followed by 10 x 1 km interval run (90% peak VO2 velocity) 12 hours later
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Both trials (T1 and T2)
Number of subjects: 10
Study: 16430570

Group type: EXPERIMENTAL
Intervention: Laryngeal Mask Airway-Classic (LMA)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Disposable Soft Seal Laryngeal Mask
Number of subjects: 60
Study: 15497716

Group type: EXPERIMENTAL
Intervention: Vardenafil
Number of subjects: 0
Study: 11524064

Group type: EXPERIMENTAL
Intervention: TTE (Transthoracic Echocardiography)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: TEE (Transesophageal Echocardiography)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Visual assessment of TTE images
Number of subjects: 57